Upstaging of ALH/LCIS Found on Core Biopsy Based on Subsequent Excisional Biopsy
Upstaging of ALH/LCIS Found on Core Biopsy Based on Subsequent Excisional Biopsy
The goal of this study is to determine how often patients who have atypical lobular
 hyperplasia (ALH) or lobular carcinoma in situ (LCIS) on core needle biopsy of an imaging
 (found by mammogram or breast ultrasound) abnormality will have associated breast cancer at
 surgical removal of the area.
Patients will undergo a breast biopsy at which the area found to be ALH or LCIS on core
 biopsy will be removed surgically through a small incision in the breast.

 -  The surgical biopsy specimen will be carefully examined by a pathologist, and may be
 useful in guiding further therapy if needed.

 -  In the future, tissue from the surgical biopsy may be used to study genetic changes that
 may be responsible for cancer formation and prevention. The tissue will be kept for
 future research for up to 10 years.
Inclusion Criteria:

 -  Women 20 years of age or older

 -  Imaging abnormality necessitating a core needle biopsy

 -  Core needle biopsy revealing ALH or LCIS

 -  Patients may have a history of fibroadenoma and/or proliferative breast lesions with
 atypia

 Exclusion Criteria:

 -  History and/or concomitant diagnosis of invasive breast cancer or ductal carcinoma in
 situ (DCIS)

 -  A palpable abnormality diagnosed by core needle biopsy to be ALH or LCIS

 -  Received tamoxifen in the past